Most Read Articles
Audrey Abella, 16 Oct 2019
The PD-1* inhibitor nivolumab showed significant survival benefit and a favourable safety profile than taxane chemotherapy in patients with unresectable advanced or recurrent oesophageal squamous cell carcinoma (OSCC) refractory or intolerant to previous fluoropyrimidine- and platinum-based chemotherapy, according to the findings of ATTRACTION-3** presented at ESMO 2019.
03 Oct 2019
Early enteral nutrition (EEN) speeds up the recovery of gastrointestinal function after laparoscopic common bile duct exploration (LCBDE), according to a study. However, EEN also increases complications such as diarrhoea and abdominal distension.
01 Sep 2019
A third of Clostridium difficile infection (CDI) patients with cirrhosis have been readmitted in a span of 30 days primarily due to recurrent CDI, a recent study has found. In addition, there is a high rate of mortality linked to CDI in patients with cirrhosis, in which a poor prognosis is predicted by decompensation and 30-day readmission.
26 Sep 2019
Use of proton pump inhibitors contributes to increased risk of cholangitis, a large cohort study suggests.

Add-on bevacizumab improves efficacy of trifluridine/tipiracil in mCRC

Elaine Soliven
11 Jul 2019

Adding bevacizumab to trifluridine/tipiracil (FTD/TPI) significantly improves progression-free survival (PFS) and overall survival (OS) compared with FTD/TPI in patients with chemorefractory metastatic colorectal cancer (mCRC), according to a study presented at ESMO GI 2019.

“The combination [of FTD/TPI and bevacizumab] … is a new option in patients with chemorefractory mCRC and could be practice-changing,” said lead author Dr Per Pfeiffer from the Department of Oncology at Odense University Hospital in Odense, Denmark.

This trial involved 93 patients with chemorefractory mCRC who were randomized to receive either oral FTD/TPI (35 mg/m2 twice daily on days 1–5 and 8–12; n=47) or FTD/TPI + bevacizumab (5 mg/kg on days 1 and 15; n=46) for a treatment cycle of 28 days. [ESMO GI 2019, abstract O-014]

Patients treated with FTD/TPI + bevacizumab experienced a significantly longer PFS compared with FTD/TPI only (median, 4.6 vs 2.6 months, hazard ratio [HR], 0.45, 95 percent confidence interval [CI], 0.29–0.72; p=0.001).

Similarly, patients who received FTD/TPI + bevacizumab achieved a significantly higher OS than those who had FTD/TPI only (median, 9.4 vs 6.7 months, HR, 0.55, 95 percent CI, 0.32–0.94; p=0.03). Thirty-seven patients were still alive after a median follow-up of 11 months, as of February 2019.

Serious adverse events occurred in 21 patients in the FTD/TPI only arm and 19 patients in the FTD/TPI + bevacizumab arm.

Grade 3–4 neutropenia was more frequent in the FTD/TPI + bevacizumab group compared with the FTD/TPI only group (67.0 percent vs 38.0 percent; p<0.05). In particular, the incidence of febrile neutropenia was higher in the FTD/TPI + bevacizumab group than in the FTD/TPI only group (events, 3 vs 1).

“[Nevertheless, the FTD/TPI + bevacizumab] therapy was well tolerated with adverse events as expected,” Pfeiffer noted.

“This trial showed for the first time that [the] addition of bevacizumab to [FTD/TPI] significantly prolonged PFS and OS [in patients with chemorefractory mCRC] … compared with FTD/TPI monotherapy, with a favourable safety profile,” he concluded.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 16 Oct 2019
The PD-1* inhibitor nivolumab showed significant survival benefit and a favourable safety profile than taxane chemotherapy in patients with unresectable advanced or recurrent oesophageal squamous cell carcinoma (OSCC) refractory or intolerant to previous fluoropyrimidine- and platinum-based chemotherapy, according to the findings of ATTRACTION-3** presented at ESMO 2019.
03 Oct 2019
Early enteral nutrition (EEN) speeds up the recovery of gastrointestinal function after laparoscopic common bile duct exploration (LCBDE), according to a study. However, EEN also increases complications such as diarrhoea and abdominal distension.
01 Sep 2019
A third of Clostridium difficile infection (CDI) patients with cirrhosis have been readmitted in a span of 30 days primarily due to recurrent CDI, a recent study has found. In addition, there is a high rate of mortality linked to CDI in patients with cirrhosis, in which a poor prognosis is predicted by decompensation and 30-day readmission.
26 Sep 2019
Use of proton pump inhibitors contributes to increased risk of cholangitis, a large cohort study suggests.